Nationwide cohort of elderly patients with coronary heart disease in China
Official title: Seniors Integrated Longitudinal cardioVascular Evaluation of Coronary Heart Disease: a Multicenter, Prospective Registry in China (SILVER-China)
Run by Beijing Hospital · NCT06880575 · Data updated 2026-11-12
This study is trying to gather health information from older patients with coronary heart disease in China to help improve their treatment and predict their health risks better.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 75 Years and up |
| Sex | All |
| Enrollment | 10139 (estimated) |
| Sponsor | Beijing Hospital Government |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | November 6, 2024 |
| Main results expected | June 30, 2027 |
| Study ends | June 30, 2027 |
| Registry record updated | March 17, 2025 |
| Trial ID | NCT06880575 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are elderly individuals aged 75 and older who have been hospitalized due to symptoms related to coronary heart disease.
✕Probably not a fit
Patients with severe non-cardiovascular diseases may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to create a comprehensive cohort and biobank of elderly patients suffering from coronary heart disease (CHD) across 50 hospitals in China. It will utilize electronic data collection to gather extensive demographic, clinical, lifestyle, and biological information from participants aged 75 and older. The goal is to develop risk prediction models and optimize clinical treatment plans based on the collected data, with long-term follow-up assessments at various intervals.
Why it matters
Potential benefit: If successful, this study could lead to improved risk assessment and treatment strategies for elderly patients with coronary heart disease.
How similar studies have gone: Other studies focusing on elderly populations with coronary heart disease have shown promise, indicating that this approach could yield valuable insights.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria:
① Age requirements: Participants are ≥ 75 years old;
* This time he was admitted to the hospital due to angina pectoris and other coronary heart disease-related symptoms
③ Conform to the diagnosis of coronary heart disease: meet any one of the following conditions:
1. This admission was performed for coronary angiography, coronary artery CTA confirmed coronary heart disease;
2. Previous clear coronary angiography, coronary artery Coronary heart disease diagnosed by imaging evidence such as CTA evidence;
3. The attending physician according to the patient's symptoms, medical history, myocardial injury markers, electrocardiogram, echo cardiography, myocardial radionuclide imaging, etc. diagnosed coronary heart disease.
④ Informed consent: Participants must be able to understand the content of the study, voluntarily participate in the study, and sign the informed consent form.
Exclusion Criteria:
* Combined with severe non-cardiovascular disease: life expectancy does not exceed 6 months, such as advanced cancer or other end-stage disease;
* Unable to cooperate with long-term follow-up: such as patients with severe cognitive impairment or severe mental illness; ③ Non-cardiogenic death within 24 hours after admission.
Where it's running
-
Beijing Hospital
Beijing, Beijing Municipality, China Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Chidamide, Lenalidomide, and Rituximab as induction therapy for newly diagnosed elderly or unfit double-expressor DLBCL
This trial tests whether the combo of chidamide, lenalidomide, and rituximab can help treat newly diagnosed double-expressor DLBCL in people who are elderly or not fit for standard chemotherapy.
-
Red grape juice and metabolism in men with coronary disease
Researchers will test whether daily red grape juice changes the blood metabolite profile in men with chronic coronary artery disease.
-
Edoxaban vs. Apixaban in AF with CAD: Net Benefit
This trial tests whether edoxaban-based therapy provides a similar or better overall benefit than apixaban-based therapy for stroke prevention and major bleeding in adults with atrial fibrillation and coronary artery disease.
-
Revascularization of Calcified Coronary Arteries
This study tests whether measuring blood flow and pressure before and after ballooning or stenting of calcified coronary arteries can help predict how well the procedure will work for adults with heart disease.
-
OPN Balloon Use for Recanalization of Calcified Coronary Lesions
This registry tests how the SIS-OPN balloon is used in real-world patients with calcified coronary disease who have undergone PCI in North America.
-
Pulse IVL to open calcified coronary vessels in CAD
A small, early feasibility study tests the Pulse Intravascular Lithotripsy system in adults with coronary artery disease to see if it can safely open calcified arteries and improve vessel compliance.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.